Determination of clinical and luteolytic effectiveness of a prostaglandin analog in mares by a dose response study

In trials covering two seasons, 124 thoroughbred and 40 quarterhorse mares with either normal cycles (55 diestrous mares, 33 postpartum mares after foal heat) or in anestrus during the breeding season (76) were treated with either a novel PGF analog K 11941 or with the PGF analog prostalene (Synchrocept(trade mark)). K 11941 was used over a range of doses from 0.5 to 4.5 mg, while prostalene was applied at the recommended dose level of 2 mg. Blood progesterone determinations, clinical observations and the results of breeding confirmed that K 11941, at doses of 2 mg or larger, and prostalene, were effective and safe luteolysins; heat and ovulations occurred within the expected time intervals and fertility was satisfactory. Clinical data were converted into a response score (CRS) and an added fertility score (CRSF) for statistical evaluation and the establishment of a dose response curve. In both scores, 0.5 to 1.5 mg were significantly less effective than the higher dose levels (p<.0001). No significant differences were found for the 2 and 3 mg dose of K 11941 in diestrous and anestrous mares. In both indications, prostalene scored less (p<.05). Data analysis and establishment of a dose response curve point to 3 mg of K 11941 as the optimal dose.     

Efficacy of a prostaglandin analogue in reproduction in the anestrous mare

A prostaglandin F analogue was studied in anestrous mares: a dose-response study; a study in mares presumed pregnant; and a field evaluation of effective doses in breeding establishments. A dose of 2.0mg given by single subcutaneous injection to mares with initial plasma progesterone levels greater than 1.0ng/ml, caused luteolysis on the basis of decline in plasma progesterone concentrations. Follicle maturation leading to ovulation, accompanied by estrus, was observed, and fertility at mating either by natural service or artificial insemination was satisfactory. A dose of 1.0mg was generally effective for luteolysis, but pregnancy rates were lower than after 2.0mg. A proportion of mares which had less than 1.0mg of plasma progesterone at the time of injection ovulated and became pregnant.     

Effects of a new injectable short-term release deslorelin in foal-heat mares

Mares treated with subcutaneous deslorelin implants on the first postpartum estrus early in the breeding season had significant reductions in the number of large follicles at early pregnancy examinations and delayed return to estrus (in mares that failed to become pregnant); these adverse effects were attributed to a prolonged release of the drug from the implant. In 2003, an injectable short-term release (<24 h) deslorelin product became available. The objective of this study was to determine if this product would hasten ovulation in early foaling first postpartum estrus mares without reducing the number of large follicles at early pregnancy examination (14-15 days postovulation). Beginning 5-6 days postpartum, first postpartum estrus (foal-heat) mares were teased daily and examined thrice weekly (Tuesday, Thursday and Saturday) by transrectal ultrasonography. Mares in estrus with a follicle > or = 34 mm diameter on Tuesdays or Thursdays were alternately assigned to: Treatment 1, n = 17; 1.5 mg injectable short-term release deslorelin, or Treatment 2, n = 16; Control (no treatment). The schedule allowed accurate determination of the number of mares ovulating within 2 days of treatment (i.e., ovulations detected on Thursday or Saturday). Mares were mated on the day of treatment and at 2-day intervals until either ovulation was confirmed or until behavioral estrus ceased. Transrectal ultrasonography was done 14-15 days after ovulation to assess ovarian follicles and pregnancy status. Fewer covers were required and more mares ovulated within 2 days of treatment in deslorelin-treated versus Control mares (P < 0.01). Pregnancy rates were normal (69%) in deslorelin-treated mares. The number of large follicles 14-15 days after ovulation did not differ between deslorelin-treated and Control mares (P > 0.10), suggesting follicular suppression did not occur with this formulation of deslorelin.     

Estrus synchronization and pregnancy rates in cyclic and noncyclic beef cows and heifers treated with syncro-mate B or Norgestomet and Alfaprostol

Postpartum lactating cows (N=118) and virgin heifers (N=60) were treated with subcutaneous Norgestomet implants for nine days and received either an intramuscular injection (im) of 5 mg estradiol valerate and 3 mg Norgestomet at the time of implant insertion or an im injection of 5 mg Alfaprostol 24 hr before implant removal. Animals were artificially inseminated 12 hr after detection of estrus. Of the cows and heifers, 78% and 88%, respectively, were in estrus within five days after implant removal (P<0.09). There was no difference between treatments in the proportion of animals in estrus or in the timing of estrus (P<0.85). Estrus was detected in a greater (P<0.05) proportion of animals that were cyclic prior to treatment (88%) than among those that were anestrous prior to treatment (77%). Pregnancy rates after five days were similar between heifers that were cyclic (42%) or anestrous (47%) prior to treatment; however, the five-day pregnancy rate in cows that were anestrous prior to treatment was 38% lower than that in cows that were cyclic prior to treatment (17 vs 55%, P<0.01). Although the treatments synchronized or induced estrus in both cyclic and anestrous animals, marked variability in estrous response and fertility among previously cyclic or anestrous postpartum cows limited the effectiveness of the treatments.     

Ultrasound and endocrine evaluation of the ovarian response to a single dose of 500 IU of eCG following a 12-day treatment with progestogen-releasing intravaginal sponges in the breeding and nonbreeding seasons in ewes

A standard dose of 500 IU of eCG is commonly given to progestogen pre-treated anestrous ewes for induction of estrus. Twelve seasonally anestrous and 12 cyclic Western White Face ewes were treated for 12 days with intravaginal sponges impregnated with medroxyprogesterone acetate (MAP). In trials in both the breeding and nonbreeding seasons, six randomly selected ewes were given 500 IU of eCG at sponge removal to determine the effects of low dose of eCG on ovarian antral follicular dynamics and ovulation. Ultrasound scanning and blood sampling were done daily. Treatment with eCG did not have marked effects on antral follicular growth. All ewes ovulated, except for five of six control anestrous ewes. Luteal structures and progesterone secretion were confirmed in all but the control anestrous ewes. In the breeding season, peak progesterone concentrations were greater (P<0.05) in eCG-treated compared to control ewes. Daily serum estradiol concentrations were greater in the periovulatory period in eCG-treated compared to control ewes (treatment-by-day interaction; P<0.05), particularly in anestrus. Progestogen-treated ewes ovulated follicles from several follicular waves, in contrast to ovulations of follicles from the final wave of the cycle in untreated, cyclic ewes. Anestrous ewes exhibited more frequent follicular waves and FSH peaks compared to cyclic ewes after a progestogen/eCG treatment. In conclusion, 500 IU of eCG given after 12 days of progestogen treatment had limited effects on the dynamics of ovarian follicular waves. However, eCG treatment increased serum concentrations of estradiol during the periovulatory period, particularly in anestrous ewes; this probably resulted in the synchronous estrus and ovulation in anestrous ewes.     

A biological embryo-reduction mechanism for the elimination of excess embryos in mares

Only one embryo was found in each of 15 pregnant mares in which multiple, synchronous (0 or 1 day apart) ovulations were induced with a pituitary extract. In the brood-farm mares, fewer (P<.05) twin pregnancies were associated with synchronous, double ovulations (0 39 ), than with asynchronous, double ovulations (9 57 ). Higher (P<.05) pregnancy rates (number of mares pregnant, regardless of number of embryos) were obtained in pituitary extract-treated mares with multiple, synchronous ovulations (15 18 ) than in treated mares with single ovulations (6 14 ). Similarily, pregnancy rates were higher (P<.01) in brood-farm mares with double, synchronous ovulations (39 47 ) than in brood-farm mares with single ovulations (1320 2426 ). Our interpretation is that ova produced by synchronous, double ovulations are viable and fertilizable (indicated by higher pregnancy rates), but that one of the resulting embryos is eliminated (indicated by the absence of twins).     

Comparison of two progestogens during out-of-season breeding in a commercial ewe flock

A comparison was made of the relative effectiveness of subcutaneous ear implants containing 2 mg Norgestomet or vagnial pessaries containing 60 mg medroxyprogesterone acetate (MAP) to induce estrus and conception in dry anestrous ewes. Groups of ewes were treated with one of the two progestogens for 14 d, and 500 IU pregnant mare serum gonadotropin (PMSG) was administered intramuscularly at the time of progestogen withdrawal. No significant differences in estrus induction, pregnancy rate or number of lambs born per ewe lambing were observed. Ewes treated with Norgestomet had 96% estrus, 60% pregnancy rate and 1.4 lambs per ewe lambing. Comparably, ewes treated with MAP had 94% estrus, 65% pregnancy rate and 1.7 lambs per ewe lambing. Norgestomet implants compared favorably with MAP pessaries for estrus induction and breeding of commercial, dry anestrous ewes.     

Estrus induction following PGF2alpha treatment in the superovulated buffalo (Bubalus bubalis)

Early return-to-estrus after embryo collection would shorten the interval between consecutive superovulations and improve efficiency of embryo production. Following superovulation and embryo collection, 80 buffaloes were treated with 15.0mg Luprostiol (PGF2alpha analogue) for the induction of luteolysis and early return-to-estrus. A total of 67.5% donor animals returned to estrus, on average 11.8+/-0.84 days after the PGF2alpha treatment. The number of ovulations (5 CL) had no significant effect on the percentage of donors returning to estrus within 30 days, as 70% of the buffaloes with 5 CL returned to estrus during this time. However, an increase in the number of ovulations significantly delayed the return to estrus as this duration was 9.7+/-0.93 days in the buffaloes with 5 CL.     

The effect of the gonadotrophin-releasing hormone analog, buserelin, administered in diestrus on pregnancy rates and pregnancy failure in mares

Two trials involving 578 mares were performed to investigate the effect of a single intramuscular treatment of 40 microg buserelin, an analog of gonadotrophin releasing hormone, on pregnancy rate in mares. All mares were bred by natural mating and were allocated into pairs One mare in each pair was injected with buserelin either on Day 10 or 11 (Trial 1) or on Days 8 to 10 (Trial 2) after ovulation. Pregnancy status of mares was determined by transrectal ultrasonographic examination on Day 14 or 15 after the day of ovulation and was repeated between Days 28 and 30 of pregnancy. In Trial 1, buserelin treatment increased the pregnancy rate at Days 14 and 15 (72.5 vs 66.6%, P < 0.01). At the second pregnancy examination, pregnancy losses were lower in the treated group of mares (4.1 vs 7.4%; P < 0.05). In Trial 2, buserelin also improved the pregnancy rate (57.2 vs 53 5%; P < 0.05) at Days 14 and 15 Pregnancy losses between the first and second examinations were lower in the treated group of mares (6.5 vs 12.0%; P < 0.05). Buserelin increased pregnancy rates after breeding at the first estrus in both trials. In addition, buserelin treatment increased the pregnancy maintenance rate at Days 28 to 30.     

Influence of reproductive stage at PRID insertion on synchronization of estrus and ovulation in mares

In the present study, we investigated the effects of reproductive status, size of follicles and plasma progesterone concentrations of mares at PRID insertion on the efficacy of the treatment, estrous cycle patterns, plasma concentrations of progesterone and LH. The progesterone-releasing device (PRID) was administered intravaginally to 28 Haflinger mares for 11 days at different reproductive stages: anestrus (n=6), estrus (n=11) and diestrus (n=11). Plasma concentrations of progesterone at insertion (Day 1) of PRID differed among treatment groups (anestrus: 0.2-0.6 ng mL(-1), estrus: 0.2-0.5 and diestrus: 1.6-10.8 ng mL(-1); P<0.001). Total secretion of progesterone (area under curve (AUC)) during treatment period revealed highest values in diestrus (38.2+/-3.1 ng mL(-1)h(-1)) followed by estrus (25.1+/-2.7) and anestrus (21.0+/-0.4 ng mL(-1)h(-1); P<0.05). Progesterone area under curve (AUC) was positively correlated with initial progesterone concentrations (R=0.5; P<0.05), but it did not correlate with the interval from PRID removal to ovulation. Plasma concentrations of LH during treatment period, were significantly lower in anestrous mares (184.6+/-28.6 ng mL(-1)h(-1)) when compared to estrous and diestrous mares (349.7+/-53.3 and 370.5+/-40.3 ng mL(-1)h(-1); P<0.05). Follicular size at PRID insertion had no effects on the intervals from PRID removal to subsequent estrus and ovulation. Follicle diameters at removal of PRID were significantly correlated with the interval from coil removal to estrus (R=-0.55, P<0.05) and ovulation (R=-0.72, P<0.0004) in cyclic mares. In anestrus 0 of 6 (0%) mares, in estrus 5 of 11 (45.5%) and in diestrus 6 of 11 (54.5%) mares ovulated within a defined interval of 1 day before to 1 day after mean interval from PRID removal to ovulation. In cyclic mares, response to treatment was significantly higher when compared to anestrous mares: almost all mares responded with estrus and ovulation independent from the stage of the estrous cycle at the start of treatment. However, accuracy of synchronization was still unsatisfactory. In cyclic mares, the plasma progesterone concentrations at insertion of PRID seem to be more important for the efficacy of the treatment than the assignment to estrous cycle stages.     

Effect of dose of GnRH analog on ovulation in mares

Proper timing of insemination for optimal conception is accomplished by frequent palpations per rectum, by ultrasonography of the preovulatory follicle and/or by treatment with hCG or GnRH. Sustained release of GnRH from implants has been shown to hasten ovulation. Therefore, 2 studies were conducted to evaluate the efficacy of a GnRH analog, deslorelin, for hastening ovulation in nonlactating cyclic mares. The GnRH implant was 2.3 x 3.7 mm and released deslorelin for 2 to 3 days. In Experiment 1, 60 nonlactating, cycling mares were assigned to 1 of 5 doses: 0, 1.2, 1.7, 2.2 and 2.7 mg per implant. Mares were assigned sequentially on the first day of estrus (Day 1). Ovaries were examined per rectum and with ultrasonography every 12 h until ovulation. Once the mares obtained a follicle >30 mm, they were injected subcutaneously with a GnRH implant. The mares were inseminated every other day during estrus with semen from 1 of 3 stallions. Pregnancy was determined with ultrasonography. Experiment 2, 40 nonlactating, cyclic mares were assigned to 1 of 5 treatments (same treatments as in Experiment 1). Data were obtained on interval to ovulation, duration of estrus and pregnancy rates at 12, 18 and 35 d after ovulation. Time to ovulation was shorter (P<0.05) in GnRH-treated mares than in control mares in the Experiment 1. Mean time to ovulation was 68, 49, 48, 47, 44 h in Experiment 1, and 91, 66, 58, 46, 58 h in Experiment 2 for mares given 0, 1.2, 1.7, 2.2 and 2.7 mg/mare in the 2 trials. Averaged for both experiments, the proportion of mares ovulating within 48 h of treatment was 40, 75, 85, 90 and 90% for 0, 1.2, 1.7, 2.2 and 2.7 mg/mare. For both experiments, there was no effect of GnRH on pregnancy rate. In summary, a subcutaneous implant containing GnRH analog induced ovulation in most mares by 48 h of injection, and there was no advantage of doses higher than 2.2 mg/mare.     

Acceleration and Timing of Fertile Ovulation in Cyclic Mares with a Deslorelin Implant

In a blinded trial, the effectiveness and safety of 2.2 mg of the GnRH analog deslorelin acetate, administered in a short–term implant (STI) to normally cycling mares in estrus with a dominant ovarian follicle of 30 mm in diameter or larger, were evaluated, using a placebo implant as a negative control. A total of 39 mares received treatments at admittance with pre–randomized implants containing either 2.2 mg or 0 mg deslorelin. Mares were teased daily and examined rectally with ultrasound at 24 h intervals to determine time to Ovulation and duration of estrus. The number of breedings and the pregnancy rate at 18 (±3) and 38 (±3) days were recorded, as were systemic side effects and local reactions at the implantation sites. Pregnancies resulting from breedings during the treatment estrus and/or from breedings during the next estrus were followed and the early and late pregnancy loss rate, the number of pregnancies going to term and of live–born foals was recorded. Mean follicle diameter at treatment was not significantly different between the deslorelin and placebo treatment group with 41.6 mm and 40.8 mm, respectively. Treatment with deslorelin STI reduced the time interval to Ovulation significantly from 69.5±25.48 h to 42.7±12.35 h (p<0.001). The percentage of mares having ovulated within 48 h rose from 26.3% to 95.0%, respectively, for placebo and deslorelin STI (p<0.001). As a consequence, the duration of estrus in days and the percent of animals requiring more than 1 breeding were significantly reduced in deslorelin treated animals from 5.4 days to 4.6 days, and from 55.6% to 5.0%, respectively (p=0.009 and =0.001). The percent of mares pregnant from breedings at the treatment estrus (65.0% versus 44.4%) or the next estrus (83.3% versus 92.3%) was satisfactory and similar for deslorelin and placebo treated mares (p>0.005), and in 70.0% and 66.7% of these once or twice bred mares did pregnancies go to term and live foals were born. kw|Keywords|k]GnRH     

Manipulation and control of the estrous cycle in pasture-based dairy cows

Treatments designed to synchronize luteolysis, preovulatory follicular development, and ovulation, and resynchronize estrus after a first AI have improved responses to synchronization treatments. Protocols based only on the use of PGF result in variable onset of estrus. Concentrations of progesterone prior to administering PGF have affected submission rates and fertility while administration of estradiol benzoate (EB) after inducing luteolysis has improved the synchrony of estrus and ovulation in some studies. In pasture-based dairy cows, GnRH-based protocols have generally resulted in one-third of both anestrous and cycling cows conceiving following synchronization of ovulation and timed AI. Protocols which use intravaginal progesterone releasing inserts (IVP4) are effective in inducing estrus in over 90% of treated dairy cows. Resynchronization of estrus after reinsertion of an IVP4 also improves the synchrony of returns to estrus, but pregnancy rates to the first AI have been reduced in some studies, and submission rates at a resynchronized estrus are less than at the first synchronized estrus. Administration of EB can be used to synchronize follicle wave emergence in resynchronized cows with intervals to new wave emergence comparable to that in cows synchronized for a first AI, but plasma concentrations of progesterone following treatment may be reduced. Synchronization of estrus and ovulation can be enhanced by administration of EB or GnRH during proestrus, but dose, timing and stage of follicular development at the time of treatment can affect outcomes.     

Inability of progestogen pretreatment to prevent premature luteolysis of induced corpora lutea in the anestrous bitch

Fourteen mature anestrous bitches were used to determine the effectiveness of pretreatment with an orally active progestogen to prevent premature luteolysis of induced corpora lutea (CL) in the anestrous bitch. In Group 1, seven bitches were treated orally with megestrol acetate (Ovaban((R))) at the rate of 2.2 mg/kg body weight for eight days. Three days later, the bitches were treated daily with pregnant mare's serum gonadotropin (PMSG) (44 IU/kg body weight) administered intramuscularly for nine consecutive days, and each bitch was given 500 IU human chorionic gonadotropin (HCG) on day 10, or on the first day of induced estrus if the bitches exhibited estrus while being treated with PMSG. A control group (Group 2) of seven bitches was not treated with Ovaban((R)) but was similarly given PMSG and HCG. Estrus was detected twice daily using a vasectomized male dog and verified by vaginal cytology. Blood samples were obtained on the first day of induced estrus (day 0) and every other day until day 90 post-estrus. Plasma progesterone (P(4)) concentrations were determined by a non-extraction solid phase radioimmunoassay (RIA), and data were analyzed by Student's t-test. There was no significant difference between the progesterone profiles of both groups of bitches. In addition, P(4) values were less than 1 ng/ml by day 50 post-estrus. Results of this study suggested that pretreatment with an orally active progestogen was not effective in preventing premature luteolysis of induced CL in the anestrous bitch.     

Response of anestrous ewes to norgestomet and PMSG

A 10-day treatment regime with a subcutaneous ear implant containing 3 mg of norgestomet, accompanied by an intramuscular injection of 1.5 mg norgestomet and 0.5 mg estradiol valerate (EV) on day 1 and 750 I. U. pregnant mares serum gonadotropin (PMSG) given intravenously on day 10, proved effective in eliciting estrus in 72% of 110 anestrous ewes within 5 days of treatment. Ewes which were treated in months closer in proximity to the normal breeding scason responded with significatly increased induction of estrus, with 71, 37, 59, 74, and 97% in estrus for ewes which were treated in February through June, respectively. Comparable estrous response in nontreated, control ewes was 0, 13, 0, 10, and 24% during February through June, respectively. (Treated vs controls, P<.01). Pregnancy rate to first service of ewes in estruc was 51% in treated and 30% in control ewes (P>.10). Overall pregnancy rate for all ewes in both groups was 36% in treated and 3% in control ewes during 5 or 16 days of breeding, respectively (P<.01).     

Induction of ovulation and multiple ovulation in seasonally-anovulatory mares with equine pituitary fractions

Equine pituitary fractions were used to induce ovulation in seasonally-anovulatory pony mares. Over three experiments, 87% of mares ovulated following twice daily injections for 14 days of equine pituitary fractions. Of the mares which ovulated, 58% had 2 or more ovulations/estrus.     

The efficacy of different hCG dose rates and the effect of hCG treatment on ovarian activity: ovulation, multiple ovulation, pregnancy, multiple pregnancy, synchrony of multiple ovulation; in the mare

Despite the widespread use of hCG to advance ovulation in the mare there is little information on efficacy of dose rates and any contraindications of its use. This study aims to investigate the effect of dose of hCG on ovulation within 48h and the effect of hCG on: ovulation, multiple ovulation (MO), pregnancy, multiple pregnancy (MP) rates and synchrony of MO; additionally whether any seasonal effect is evident. Sequential ultrasonic scanning was used to monitor the occurrence of ovulation, within 48h of treatment, in 1291 Thoroughbred mares treated with either 750iu hCG or 1500iu hCG s.c. Ovulation rate, type (single ovulations (SO), MO, synchronous, asynchronous) and subsequent pregnancy were then monitored in 1239 Thoroughbred mares on a commercial stud over 3 years, 536 of which were treated with 750iu hCG at mating, all mares were also allocated into groups according to month of mating. No significant difference existed between the two dose levels of hCG and no significant difference existed between treated and untreated mares in overall ovulations (1.32 and 1.28 respectively), MO (31.7% and 27.7%), pregnancy (65.1% and 65.6%) or MP rates (10.8% and 11.8%). There was no significant association between month of year and pregnancy or MP rates for either treated or control mares, nor for MO for untreated mares. A significant (p<0.05) association was evident between month and MO in treated mares, MO being lowest in April (22.3%). 95.9% of treated mares multiple ovulated within 48h compared with 90.7% controls, a near significant difference. In conclusion this study demonstrates that: (i) hCG dose of 750iu s.c. is just as effective in inducing ovulation within 48h as 1500iu, (ii) 750iu hCG has no significant effect on ovulation, MO, pregnancy or MP rates; (iii) a significant (p<0.05) association exists between season and MO in hCG treated mares; (iv) a tighter synchrony (ovulation within 48h) of MO is evident in hCG treated compared with control mares (p=0.052).     

Clinical evaluations of a new prostaglandin analog in pigs: 1. Control of parturition and of the MMA-syndrome

In two field trials, the parturition inducing and MMA preventing effects of the prostaglandin F(2alpha) analog (PGFA), K 11941, were explored. In trial 1, 100 sows were treated with 2 mg and 30 with 3 mg of K 11941 i.m. on day 112 of gestation; 125 sows treated on day 112 with 175 mcg cloprostenol (Planate, ICI) served as positive controls, and 248 sows treated with saline on day 112 of gestation were used as negative controls. Both PGF analogs were equally effective in inducing early parturiton: 84.6% and 83.2% of the sows had farrowed between 20 and 30 hours after treatment. Both treatments reduced stillbirth rate and piglet losses during the first 10 days of life, and lowered the incidence of MMA significantly (6.2 and 5.6% vs 27.3 and 24.2%; p<.001). In a second trial, parturitions were induced in four groups of 60 sows each with 2 mg K 11941, housed in farms with either a chronic high incidence of MMA (A: 45 to 65% or only a seasonal rise in MMA during summer (B: 10 to 50%). Groups were treated either in April/May or August/September; 240 salinetreated, control sows were used. K 11941-induced parturition reduced MMA incidence in farm A during both seasons and prevented the summer rise in farm B (p<.01). Fertility after weaning was impaired in herds with an increased incidence of MMA.     

Induction of ovulation during the postpartum period in the thoroughbred mare with a prostaglandin analogue,Synchrocept™

Breeding of mares at the foal heat is desirable, but the low pregnancy rate and the not infrequent occurrence of subsequent anestrus are a deterrent. A PGF_2a analogue, Synchrocept^? (prostalene), as a single 2 mg subcutaneous injection was used to induce ovulation, either during the corpus luteum phase subsequent to a foal heat (test group 1) or at a fixed interval of 20 days from parturition (test group 2) in mares that also had a foal heat. Mares with no signs of a foal heat were treated 20 days postpartum (test group 3). A total of 80, mostly Thoroughbred, mares were treated in more than 15 breeding centers in Northern Germany between mid-January and mid-May 1975. At the same locations and over the same time periods, 60 control mares (control group 1) were bred at the foal heat and 40 additional control mares (control group 2) were bred later than 25 days postpartum.In groups 1 and 2, treatment induced estrus in 95% of the mares and in group 3 estrus was induced in 68% of the mares. Of these animals, 92% were bred and 81% conceived on the average 28 days after parturition. The number of services per conception in mares treated was 25% lower (2.5) than in controls (3.2). Synchrocept acted as a luteolysin, but seems also to have induced heat and estrus in animals with plasma progesterone levels below 1 ng/ml, as has been reported previously. Neither mares nor foals showed detectable clinical signs of drug intolerance.     

Progesterone profiles in postpartum Holstein dairy cows as an aid in the study of retained fetal membranes, pyometra and anestrus

This study was carried out to investigate the utility of enzymeimmunoassay (EIA) - derived progesterone profiles in the investigation of postpartum reproductive abnormalities and the effect of their use on reproductive performance in Holstein cows. Whole milk samples, collected twice weekly from parturition until confirmation of pregnancy or removal from the herd, were assayed for progesterone (P4) concentration using a commercially available microtitre plate EIA. The sensitivity, specificity, precision and accuracy were satisfactory to distinguish cyclic changes of P4 reflecting ovarian activity. The P4 profiles indicated that retained fetal membranes and anestrus were associated with increased mean intervals to first ovulation and first estrus (P < 0.05). The first luteal phase of cows with pyometra was prolonged compared with that of normal herdmates (P < 0.05). Anestrus cows had an increased number of ovulations before first service and before pregnancy (3.9 and 5.9) in comparison with normal herdmates (2.1 and 3.5; P < 0.05). Calving to pregnancy interval was increased above normal (74.8) for pyometra (125.0) and anestrus (152.7) (P < 0.05). Pregnancy rate for anestrus cows (82%) was lower than for normal cows (100%) and more anestrous cows were culled (27%) than normal cows (5%) (P < 0.5). The P4 profiles indicated that the major problem in the herd studied, anestrus (32% incidence rate), was most likely due to the failure to observe estrus rather than acyclicity.